Regenxbio presents phase 1 data for wet AMD gene therapy

CHICAGO — The 6-month results of an ongoing phase 1 study evaluating RGX-314 gene therapy for patients with wet AMD showed positive safety and patient tolerability outcomes, according to a speaker here.
The therapy is designed to deliver a gene encoding for an anti-VEGF fab protein. The therapy is delivered subretinally, and the RGX-314 therapy uses a proprietary gene delivery platform, hypothesized to deliver longer and higher protein levels with a lower immune response, Jeffrey Heier, MD, lead researcher of the study said at a Regenxbio press briefing after he (Read more...)

Full Story →